TickerFacts.

Company research / AGEN

Agenus Inc (AGEN)

Build a valuation ↗↓ Download CSV

SEC name AGENUS INC · CIK 0001098972 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Agenus Inc reported revenue of $114.20M. Revenue grew 10.4% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $132.69M.

Key ratios (year ended 2025-12-31)

-17.7%
Operating margin
-2.7%
Net margin
10.4%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-02

Headquarters locality: Lexington · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$132.69M$114.20M$103.46M$156.31M$98.02M$295.67M$88.17M$150.05M$36.78M$42.88M$22.57M
Cost of Revenue$642.0K$1.02M$486.0K$3.11M$10.57M$3.47M$2.35Mn/an/an/an/a
Gross Profit (computed)n/an/an/an/a$87.46Mn/an/an/an/an/an/a
R&D Expense$57.69M$79.34M$155.53M$234.57M$186.69M$178.61M$142.62M$168.34M$124.60M$116.12M$94.97M
Operating Income$36.20M-$20.17M-$120.47M-$159.55M-$179.43M$25.75M-$117.23M-$70.14M-$123.82M-$103.80M-$107.48M
Depreciation & Amortization$4.73M$10.00M$13.34M$13.59M$6.95M$6.79M$7.18M$6.66M$6.29M$6.01M$4.95M
EBITDA$40.93M-$10.17M-$107.13M-$145.96M-$172.48M$32.53M-$110.06M-$63.48M-$117.53M-$97.80M-$102.53M
Net Income$91.94M-$3.08M-$232.27M-$257.44M-$230.66M-$28.72M-$182.89M-$111.56M-$162.04M-$120.69M-$127.00M
EPS (Diluted)n/a$0.00-$10.59-$13.75-$15.64-$0.11-$1.05n/an/an/an/a
Total Assets$172.69M$226.80M$226.27M$313.91M$413.56M$465.96M$214.51M$155.34M$136.40M$138.40M$156.99M
Long-Term Debt$30.07M$44.66M$33.17Mn/an/an/an/an/an/an/an/a
Shareholders' Equity-$199.07M-$271.11M-$326.38M-$160.33M-$61.28M$34.44M-$203.67M-$225.36M-$172.47M-$75.82M-$39.13M
Cash & Equivalents$18.74M$3.00M$40.44M$76.11M$178.67M$291.93M$99.87M$61.81M$53.05M$60.19M$71.45M
Operating Cash Flow-$98.50M-$77.19M-$158.31M-$224.20M-$175.37M$10.14M-$139.10M-$18.68M-$131.09M-$94.23M-$79.96M
Capital Expenditures$0$6.0K$576.0K$9.95M$53.06M$33.81M$3.47M$4.66M$3.60M$3.12M$12.52M
Free Cash Flow-$98.50M-$77.20M-$158.89M-$234.16M-$228.44M-$23.67M-$142.56M-$23.34M-$134.69M-$97.35M-$92.48M
Shares Outstanding42.62M35.32M23.63Mn/an/an/an/an/an/an/an/a
Weighted Average Diluted Sharesn/a29.73M21.47M17.89M14.09Mn/an/an/an/an/an/a
EPS (Basic)n/a$0.00-$10.59-$13.75-$15.64-$0.11-$1.05n/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView